Immunocore’s (IMCR) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a report issued on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $71.00 price objective on the stock.

IMCR has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Wednesday. Morgan Stanley restated an “equal weight” rating and issued a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Up 1.9 %

NASDAQ:IMCR opened at $28.80 on Wednesday. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -30.32 and a beta of 0.79. Immunocore has a one year low of $27.19 and a one year high of $66.00. The stock has a 50-day simple moving average of $30.08 and a 200 day simple moving average of $31.38. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in shares of Immunocore during the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after buying an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares during the last quarter. Tema Etfs LLC bought a new stake in shares of Immunocore during the fourth quarter valued at approximately $330,000. Finally, Virtus ETF Advisers LLC raised its holdings in Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after purchasing an additional 3,238 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.